CO7141430A2 - Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación - Google Patents

Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación

Info

Publication number
CO7141430A2
CO7141430A2 CO14249925A CO14249925A CO7141430A2 CO 7141430 A2 CO7141430 A2 CO 7141430A2 CO 14249925 A CO14249925 A CO 14249925A CO 14249925 A CO14249925 A CO 14249925A CO 7141430 A2 CO7141430 A2 CO 7141430A2
Authority
CO
Colombia
Prior art keywords
pain
treatment
joint
reduced mobility
vesicular
Prior art date
Application number
CO14249925A
Other languages
English (en)
Spanish (es)
Inventor
Richard Wolf Garraway
Michael Earl
Saruhan Yurdakul
Nicholas Baverstock
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Publication of CO7141430A2 publication Critical patent/CO7141430A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO14249925A 2012-04-12 2014-11-12 Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación CO7141430A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1206486.1A GB201206486D0 (en) 2012-04-12 2012-04-12 Vesicular formulations and uses thereof

Publications (1)

Publication Number Publication Date
CO7141430A2 true CO7141430A2 (es) 2014-12-12

Family

ID=46208989

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14249925A CO7141430A2 (es) 2012-04-12 2014-11-12 Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación

Country Status (26)

Country Link
US (3) US20150065461A1 (enExample)
EP (1) EP2836203B1 (enExample)
JP (1) JP2015512926A (enExample)
KR (1) KR102204725B1 (enExample)
CN (1) CN104363894B (enExample)
AU (1) AU2013246822A1 (enExample)
BR (1) BR112014025507B1 (enExample)
CA (1) CA2870111A1 (enExample)
CL (1) CL2014002706A1 (enExample)
CO (1) CO7141430A2 (enExample)
DK (1) DK2836203T3 (enExample)
EA (1) EA039626B1 (enExample)
ES (1) ES2916803T3 (enExample)
GB (2) GB201206486D0 (enExample)
HR (1) HRP20220700T1 (enExample)
HU (1) HUE058972T2 (enExample)
IL (1) IL234862A0 (enExample)
IN (1) IN2014DN08259A (enExample)
LT (1) LT2836203T (enExample)
MX (1) MX2014012198A (enExample)
PH (1) PH12014502079A1 (enExample)
PL (1) PL2836203T3 (enExample)
PT (1) PT2836203T (enExample)
SG (1) SG11201406251VA (enExample)
SI (1) SI2836203T1 (enExample)
WO (1) WO2013153221A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
DK3316857T3 (da) 2015-06-30 2021-10-18 Sequessome Tech Holdings Limited Multifasiske sammensætninger
HRP20230566T1 (hr) * 2017-08-22 2023-08-18 Moebius Medical Ltd. Liposomalna formulacija za podmazivanje zglobova
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドAmpersand Biopharmaceuticals Inc. 投与および処置の方法
CN110314137B (zh) * 2018-03-30 2022-04-05 北京泰德制药股份有限公司 一种含有脂质囊泡的冻干制剂
KR20230041954A (ko) 2021-09-17 2023-03-27 서울대학교산학협력단 골관절염 예방 또는 치료용 약학 조성물 및 건강기능식품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4327193A (en) * 1992-07-08 1994-01-31 Dianorm-Gerate G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
AUPN723395A0 (en) * 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
CA2448627A1 (en) * 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
US7115666B2 (en) * 2002-10-15 2006-10-03 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
CN101541308B (zh) * 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
AU2010255391C1 (en) * 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) * 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
US9125786B2 (en) * 2011-03-31 2015-09-08 Phillip Anthony FEMANO Method and device to alleviate carpal tunnel syndrome and dysfunctions of other soft tissues
CN105229171A (zh) * 2013-03-13 2016-01-06 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物

Also Published As

Publication number Publication date
BR112014025507B1 (pt) 2022-01-04
ES2916803T3 (es) 2022-07-06
DK2836203T3 (da) 2022-06-07
IL234862A0 (en) 2014-12-31
EP2836203B1 (en) 2022-03-09
GB2515439A (en) 2014-12-24
CN104363894A (zh) 2015-02-18
WO2013153221A1 (en) 2013-10-17
IN2014DN08259A (enExample) 2015-05-15
GB201419074D0 (en) 2014-12-10
US20210393655A1 (en) 2021-12-23
PT2836203T (pt) 2022-06-15
EP2836203A1 (en) 2015-02-18
BR112014025507A2 (pt) 2017-08-08
EA201491583A1 (ru) 2015-05-29
CL2014002706A1 (es) 2015-04-24
US20170128473A1 (en) 2017-05-11
CA2870111A1 (en) 2013-10-17
GB201206486D0 (en) 2012-05-30
HUE058972T2 (hu) 2022-09-28
LT2836203T (lt) 2022-06-10
SI2836203T1 (sl) 2022-07-29
CN104363894B (zh) 2016-11-23
US20150065461A1 (en) 2015-03-05
AU2013246822A1 (en) 2014-10-16
KR20150008869A (ko) 2015-01-23
SG11201406251VA (en) 2014-10-30
JP2015512926A (ja) 2015-04-30
PL2836203T3 (pl) 2022-07-11
PH12014502079A1 (en) 2014-12-10
HRP20220700T1 (hr) 2022-07-08
MX2014012198A (es) 2015-06-04
EA039626B1 (ru) 2022-02-17
KR102204725B1 (ko) 2021-01-19
GB2515439B (en) 2017-08-23

Similar Documents

Publication Publication Date Title
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
PE20180399A1 (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
AR089993A1 (es) Macrociclos peptidomimeticos
MX2015003239A (es) Composiciones topicas y metodos de uso.
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
GT201400043A (es) Imidazopiridazinas sustituidas con amino
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PE20151759A1 (es) Imidazopiridazinas sustituidas
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
MX383944B (es) Composiciones para el cuidado personal.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
MX373714B (es) Composiciones de ketoprofeno de accion prolongada.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
MX2014003051A (es) Composiciones para el tratamiento de ulceras perifericas de diversos origenes.
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
UY35981A (es) Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol
NI201200196A (es) Agentes terapéuticos 976
BR112015020182A2 (pt) uso cosmético de queuina ou de um precursor ou um derivado dessa como ingrediente ativo, uso de queuina ou um precursor ou um derivado dessa como ingrediente ativo, composição cosmética e processo de tratamento cosmético para prevenir e/ou tratar sinais de envelhecimento da pele e/ou anexos cutâneos